文献速递消化道肿瘤放疗

调强放射治疗用于局部晚期胰腺癌的临床评价

Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer.
PubMed 文献 · Radiat Oncol · 2018-06-25

该回顾性研究纳入2001年9月至2015年3月间107例接受放化疗的局部晚期胰腺癌患者,其中80例接受三维适形放疗(3DCRT)、27例接受调强放疗(IMRT),比较两组胃肠道毒性及生存结局。IMRT组1年无局部区域进展生存率和1年总生存率均优于3DCRT组,且急性≥2级胃肠道毒性发生率低于3DCRT组。

要点

  • IMRT组1年无局部区域进展生存率73.1% vs 3DCRT组63.2%(p=0.035)。
  • IMRT组1年总生存率92.3% vs 3DCRT组68.2%(p=0.037)。
  • IMRT组急性≥2级胃肠道毒性5例(19%)vs 3DCRT组32例(40%)。

核心结论

  • 与常规分割低剂量吉西他滨3DCRT相比,大分割全剂量吉西他滨IMRT治疗的局部晚期胰腺癌患者总生存和无局部区域进展生存改善,且胃肠道毒性未增加。
  • 在IMRT患者中,较高剂量(≥45 Gy)是更好无局部区域进展生存和总生存的独立有利预后因素,作者认为IMRT剂量递增对局部晚期胰腺癌是有前景的策略。

研究设计与样本

  • 回顾性评价2001年9月至2015年3月连续107例接受放化疗的局部晚期胰腺癌患者,其中80例接受3DCRT、27例接受IMRT。
  • 比较两组胃肠道毒性、无局部区域进展生存、无远处转移生存和总生存。

主要发现

  • 3DCRT和IMRT的中位放疗剂量与分次分别为54 Gy/30次和48 Gy/15次。
  • 放化疗方案为每周吉西他滨250 mg/m2(3DCRT)或1000 mg/m2(IMRT)。
  • 急性≥2级胃肠道毒性发生于3DCRT组32例(40%)vs IMRT组5例(19%)。
  • 3级晚期胃肠道毒性发生于3DCRT组10例(12%)vs IMRT组1例(4%)。
  • IMRT组1年无局部区域进展生存率73.1% vs 3DCRT组63.2%(p=0.035),1年总生存率92.3% vs 68.2%(p=0.037)。

关键数值与推荐

  • 多因素分析显示,在IMRT患者中较高剂量(≥45 Gy)是更好无局部区域进展生存和总生存的独立因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose was to retrospectively evaluate the effect of intensity-modulated radiotherapy (IMRT) on gastrointestinal (GI) toxicities and outcomes compared to three-dimensional conformal radiotherapy (3DCRT) for locally advanced pancreatic cancer (LAPC). METHODS: We included 107 consecutive patients who underwent CRT for LAPC from September 2001 to March 2015; 80 patients underwent 3DCRT and 27 patients underwent IMRT. They were compared for GI toxicities, locoregional progression free survival (LRPFS), distant metastasis free survival (DMS), and overall survival (OS). RESULTS: Median radiation dose and fractions for 3DCRT and IMRT were 54 Gy/30 fr. and 48 Gy/15 fr. The regimens of CRT consisted of weekly gemcitabine 250 mg/m2 (for 3DCRT) or 1000 mg/m2 (for IMRT). Acute GI toxicity ≥grade 2 occurred in 32 patients (40%) treated with 3DCRT compared with five patients (19%) treated with IMRT. Late GI toxicity of grade 3 occurred in 10 patients (12%) treated with 3DCRT and one patient (4%) treated with IMRT. Patients who underwent IMRT had superior 1-year LRPFS (73.1% vs. 63.2%, p = 0.035) and 1-year OS (92.3% vs. 68.2%, p = 0.037) as compared with those treated with 3DCRT. Multivariate analysis showed that in IMRT patients, higher dose (≥45 Gy) was an independent factor for better LRPFS and OS. CONCLUSIONS: LAPC patients treated with hypofractionated full-dose gemcitabine IMRT had improved OS and LRPFS without increased GI toxicities when compared to those of patients treated with conventionally fractionated low dose gemcitabine 3DCRT. In IMRT patients, higher dose was an independent favorable prognostic factor for better LRPFS and OS, which suggests that dose escalation with IMRT for LAPC is a promising strategy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Goto Y, Nakamura A, Ashida R, et al. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2018. PMID: 29940984. doi:10.1186/s13014-018-1063-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。